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ABSTRACT 
Background. In young individuals, a genetically predisposing hypercoagulability and classic 
modifying risk factors can act synergistically on the ischemic stroke risk development. The 
aim of the study was to compare the prevalence of classic vascular risk factors and 
polymorphisms of the G20210A coagulation factor II (prothrombin), Arg506Glu coagulation 
factor V Leiden, C677T methylenetetrahydrofolate reductase (MTHFR) and 4G/5G 
plasminogen activator inhibitor-1 (PAI-1) and the impact of these gene mutations and classic 
vascular risk factors on the overall stroke risk in individuals aged <55.  
Methods. The study included 155 stroke patients aged ≤55 and 150 control subjects. Stroke 
prevalence and odds ratio (OR) were assessed for the following parameters: G20210A 
prothrombin, Arg506Glu factor V Leiden, C677T MTHFR and 4G/5G PAI-1 polymorphisms; 
total number of study polymorphisms in a particular subject (genetic sum), and classic 
vascular risk factors of hypertension, obesity, diabetes mellitus, cigarette smoking, 
hypercholesterolemia, hypertriglyceridemia, and elevated levels of LDL-cholesterol and 
VLDL-cholesterol.  
Results. The prevalence of hypertension (p<0.001), smoking (p<0.001), decreased HDL-
cholesterol levels (p<0.001), obesity (p=0.001), elevated LDL-cholesterol (p=0.036), C677T 
MTHFR polymorphism (p<0.001) and genetic sum was significantly higher in the group of 
stroke patients. The following parameters were found to act as independent risk factors for 
ischemic stroke: decreased HDL-cholesterol level (p<0.001; OR 4.618; 95%CI 2.381-8.957); 
hypertension (p=0.001; OR 2.839; 95%CI 1.519-5.305); obesity (p=0.040; OR 2.148; 95%CI 
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1.036-4.457); smoking (p=0.001; OR 2.502; 95%CI 1.436-4.359); and genetic sum as a 
continuous variable (p<0.01; OR 2.307; 95%CI 1.638-3.250). 
Conclusions. Gene mutations of the procoagulable and proatherosclerotic factors investigated 
exerted a synergistic action in the development of overall risk of ischemic stroke in young and 
middle-aged individuals. 
 
Introduction 
Although ischemic stroke occurs mainly in elderly individuals aged ≥65, nowadays it 
is increasingly found in young individuals, even in children. According to various 
epidemiological studies, the incidence of stroke in subjects aged <55 ranges from 7 to 11 per 
100,000 [1,2]. 
In most cases, ischemic stroke is a multifactorial disease with genetic predisposition, 
while the inherited risk is likely to be multigenic [3-5]. Research results suggest that the 
genetic predisposition might primarily influence the etiopathogenesis of premature ischemic 
stroke in young and middle-aged individuals [6-8].  
Recent studies have confirmed the role of the prothrombotic factor gene mutations in 
the development of venous thrombosis, whereas their impact on the occurrence of arterial 
events has not yet been clarified. The role of different prothrombotic and proatherogenic 
polymorphisms in the pathogenesis of ischemic stroke has been investigated [9-13]. Among 
them, the G20210A polymorphism of the prothrombin gene, the G1691A polymorphism of 
the factor V gene, the C677T polymorphism of the methylentetrahydrofolate reductase 
(MTHDR) gene and the 4G/5G polymorphism of the plasminogen activator inhibitor-1 (PAI-
1) are the most frequently studied. Some studies failed, but others did demonstrate the 
association of these polymorphisms with the risk of ischemic stroke [6-12]. Results from 
these studies address the weak effect of single genetic marker on the stroke risk development; 
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it might be stronger in younger individuals and in mutually cumulative interactions of 
different polymorphisms. To date, we are aware of just few studies that have investigated 
cumulative effect of these prothrombotic and proatherogenic polymorphisms on the stroke 
risk development [6,10]. 
The aim of the present study was to determine and compare the prevalence of classic 
vascular risk factors and polymorphisms of the G20210A coagulation factor II, Arg506Glu 
coagulation factor V Leiden, C677T MTHFR and 4G/5G plasminogen activator inhibitor-1 in 
the group of younger stroke patients and age- and sex-matched control group. In addition, the 
impact of these gene mutations and classic vascular risk factors on the overall stroke risk in 
individuals aged <55 was assessed. 
 
Subjects and Methods 
This prospective study was conducted at University Department of Neurology, Sestre 
milosrdnice University Hospital Center in Zagreb, Croatia, from June 2009 to January 2012. 
 Study protocol was consistent with ethical principles of medical profession and was 
approved by the Ethics committee Sestre milosrdnice University Hospital Center. All study 
subjects were informed on all the procedures to be used during the study and provided their 
written informed consent on participation in the study.  
The study included 155 successive ischemic stroke patients younger than 55 and 150 
age- and sex-matched control subjects. Clinical diagnosis of ischemic stroke was based on the 
computed tomography (CT) and magnetic resonance (MR) evidence for cerebral infarct.  
Complete demographic and history data on age, sex and classic vascular risk factors 
for stroke, including hypertension, diabetes mellitus, cigarette smoking, hyperlipidemia and 
body weight were collected from both stroke patients and control subjects. Hypertension was 
determined on the basis of systolic blood pressure greater than 160 mm Hg or/and diastolic 
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blood pressure greater than 95 mm Hg measured at two time points at least two weeks after 
acute phase of ischemic stroke, or if the patient had been on antihypertensive therapy before 
inclusion in the study. Diabetes mellitus was diagnosed according to the World Health 
Organization (WHO) criteria [14]. According to smoking habits, study subjects were divided 
into two groups of current smokers and nonsmokers, the latter including those that had ceased 
smoking more than six months before. Hypercholesterolemia was defined as cholesterol 
levels exceeding 5 mmol/L or taking cholesterol lowering agents. Decreased HDL-cholesterol 
levels were defined as <1.2 mmol/L in female and <1.0 mmol/L in male subjects. Elevated 
LDL-cholesterol levels were defined as >3.0 mmol/L. Elevated triglyceride levels were 
defined as >1.7 mmol/L. Body mass index (BMI; body weight divided by square body height) 
was calculated in all study subjects, classifying them into three groups of normal weight (BMI 
<25), overweight (BMI 25-29.99) and obese (BMI >30) subjects. 
Study patients underwent brain CT, color Doppler sonography and transcranial 
Doppler of carotid arteries, brain MR, cerebral MR panangiography, electrocardiography, 
lung x-ray, transthoracic and/or transesophageal echocardiography, and urine biochemistry. 
Blood samples were obtained for determination of complete blood count (CBC), erythrocyte 
sedimentation rate (ESR), coagulation tests and fibrinogen, blood glucose, lipidogram, and 
coagulation factors II and V, MTHFR and PAI-1 polymorphisms. 
To investigate any potential association between the studied polymorphisms and 
specific subtypes of infarct, we created modified Trial of ORG 10172 in Acute Stroke 
Treatment classification accommodated for stroke in the young; accordingly patients were 
divided in five major etiologic categories: (1) atherosclerosis; (2) cardiac embolism; (3) 
cervical artery dissection; (4) other known, rare causes and (5) cryptogenic stroke. 
Control group included 150 subjects treated for vertebrogenic disorders as part of the 
cervicobrachial and lumbosacral syndrome at Pain Clinic, University Department of 
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Neurology, Sestre milosrdnice University Hospital Center from June 2009 to January 2012. 
Control subjects were age- and sex-matched to ischemic stroke patients, had no known history 
of vascular or thromboembolic disease, and had normal neurologic status. All study subjects 
were Caucasians, originating from the same geographical area, and were of comparable social 
status. 
Venous blood samples were obtained from both stroke patients and control subjects 
for molecular diagnosis and determination of coagulation factor II, coagulation factor V, PAI-
1 and MTHFR polymorphisms. All study polymorphisms were determined by the 
standardized polymerase chain reaction-restriction fragment length polymorphism (PCR-
RFLP) method. 
Total number of classic vascular risk factors (range 0-8) and total number of gene 
polymorphisms under study (range 0-4) as genetic sum were calculated in each study subject. 
The normality of numerical data distribution was tested by Kolmogorov-Smirnov test. 
As most of the numerical data did not follow normal distribution, nonparametric statistical 
tests were employed in the analysis.  
Mann-Whitney test was used to compare numerical data between two independent 
groups of patients and control subjects. Kruskal-Wallis test was used to compare more than 
two independent groups of numerical data divided according to the genetic sum into five 
groups. In case of statistically significant difference, multiple testing of particular group pairs 
was performed using Mann-Whitney test with Bonferroni correction for multiple testing. 
Categorical characteristics were tested by χ
2
-test whenever possible; otherwise, Fisher 
exact test was employed. In addition to testing the existence of associations, the strength of 
associations was assessed using odds ratio with the corresponding 95% confidence interval 
(95%CI). 
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Ischemic stroke prediction with the potential classic and genetic predictors and their 
interactions were analyzed by use of multivariate logistic regression as follows: a wider set of 
predictors defined by clinical and statistical evaluation, included in the initial model of 
logistic regression. All predictors at the level of statistical significance of p<0.2 were chosen 
from the initial model of logistic regression. Then, nonsignificant predictors at the level of 
statistical significance of p<0.05 were excluded from the logistic model. The potentially final 
model of logistic regression was analyzed for the possible interactions and impact of all 
excluded predictors, so that every excluded predictor was reintroduced in the model to 
analyze its impact on the significance of predictors in the potentially final model. If a 
previously excluded predictor modified the significance of chosen predictors by more than 
20%, the excluded predictor was returned to the final model. 
The Microsoft Excel 2003 software was used on data processing and R Version 2.10.1 
software on statistical analysis. 
 
Results 
The study included 305 subjects in total, i.e. 155 ischemic stroke patients and 150 
control subjects. There were no statistically significant between-group age (p=0.121; Mann-
Whitney test) and sex (p=0.778; χ
2
-test) differences. 
Patient/subject distribution according to the presence of classic vascular stroke risk 
factors and studied polymorphisms is illustrated in Table 1. Hypertension, current smoking, 
decreased HDL-cholesterol, obesity (p=0.001; χ
2
-test all) and elevated LDL-cholesterol 
(p=0.036; χ
2
-test) were statistically significantly more frequently recorded in the group of 
ischemic stroke patients. A statistically significant between-group difference was found in the 
distribution of MTHFR genotype (p<0.001; χ
2
-test).  
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There was a statistically significant between-group difference in the total number of 
study polymorphisms (genetic sum) in individual subjects (p<0.001; Mann-Whitney test) 
(Table 2). Concurrence of all four single nucleotide polymorphisms under study was not 
recorded in any of the study patients/control subjects.  
There were 99 (63,87%) patients with established cause of stroke: atherosclerotic 
vasculopathy in 46 (29,67%) patients, cardiac embolism in 30 (19,36%) patients, cervical 
artery dissection in 13 (8,39%) patients, other rare causes of stroke were established in 10 
patients (6,45%); while in 56 (36,13%) patients cause of stroke remains undetermined and 
they formed a group of  cryptogenic stroke. Patients with cryptogenic stroke were somewhat 
younger, but the difference is on the border of statistical significance (p=0,050; Kruskal-
Wallis test).  
Hypertension (p<0,001; χ
2
-test), current smoking (p<0,001; χ
2
-test), obesity (p=0.001; 
χ
2
-test), elevated LDL-cholesterol (p=0.036; χ
2
-test) and decreased HLD-cholesterol 
(p<0,001; χ
2
-test) were statistically significantly more frequently recorded in the group of 
noncryptogenic stroke patients. There was a statistically significant between-group difference 
in the total number of classic vascular risk factors (p=0,002; Mann-Whitney test) and in the 
distribution of MTHFR (p<0.001; χ
2
-test) and PAI-1 genotype (p<0.001; χ
2
-test). There was a 
statistically significant between-group difference in the total number of study polymorphisms 
(genetic sum) in individual subjects (p<0.001; χ
2
-test) (table 3).    
The following variables were included in the initial model of multivariate logistic 
regression: age, sex, prothrombin G20210A, factor V Leiden Arg506Glu, MTHFR C677T 
and PAI-1 4G/5G polymorphisms, genetic sum = 3, genetic sum = 1, genetic sum = 2, 
elevated total cholesterol, decreased HDL-cholesterol, elevated LDL-cholesterol, elevated 
triglycerides, hypertension, obesity, diabetes and cigarette smoking as potential predictors of 
the ischemic stroke risk significance. 
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Based on the initial logistic regression with the criterion of variable significance in the 
model of >0.2, the second model of logistic regression was designed in two versions. The 
following variables were included in model version (A): age, prothrombin G20210A, factor V 
Leiden Arg506Glu, MTHFR C677T and PAI-1 4G/5G polymorphisms, elevated total 
cholesterol, decreased HDL-cholesterol, hypertension, obesity and smoking. The other model 
version (B), following the same procedure, included the variables of age, elevated total 
cholesterol, decreased HDL-cholesterol, hypertension, obesity, smoking, and genetic sum as a 
continuous variable instead of particular polymorphisms. Classification accuracy at the 
univariate level of 72.1% and 71.5%, respectively, was determined for both versions of the 
second multivariate logistic model. The model was statistically significant (p<0.001). 
Based on the final logistic model results, nonsignificant variables were excluded; these 
were elevated total cholesterol levels, prothrombin G20210A polymorphism, factor V Leiden 
Arg506Glu polymorphism and PAI-1 4G/5G polymorphism in the (A) version, and elevated 
total cholesterol and obesity in the (B) version of the second multivariate logistic model. As 
either particular polymorphisms or genetic sum were included in the model of multivariate 
logistic regression, and the genetic sum proved to be superior to particular polymorphisms as 
a predictor, the latter was left in the final model. The MTHFR C677T polymorphism was not 
included in the final model due to nonsignificance of other polymorphisms making the whole 
of prediction system; therefore, inclusion of the genetic sum was concluded to be more useful. 
Since the MTHFR C677T polymorphism plays a role in the genetic sum formation, their 
concurrence in the model would pose a problem of multi-colinearity and possible separation 
of nonsignificant predictors as significant ones with their taking over the predictive role. 
The final model of logistic regression of the risk factor significance in the 
development of ischemic stroke included the following variables: age, decreased HDL-
cholesterol, hypertension, obesity, cigarette smoking, and genetic sum as a continuous 
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variable (Table 4). This multivariate logistic model yielded a classification accuracy of 
69.8%. The model was statistically significant (p<0.001). The impact of excluded variables on 
the final regression model was assessed by a series of statistical testing for each individual 
variable, and their contribution to model modification did not exceed 20% of the statistical 
significance (p value). The suspicion of the possible effect of these variables was thus 
dissipated and there was no need to return them in the final model. 
 
Discussion 
Our study results indicated the classic vascular risk factors of elevated LDL-
cholesterol, cigarette smoking, hypertension, decreased HDL-cholesterol and obesity to be 
statistically significantly more common in the group of young and middle-aged ischemic 
stroke patients. A very similar profile of classic vascular risk factors in young ischemic stroke 
patients has also been reported elsewhere, however, differing in the order of frequency [3-
7,15-19]. These results show that conventional vascular risk factors are significant risk factors 
for ischemic stroke not only in the >55 age group, but also in younger population. 
Like most other studies, the present study was a pair study with the candidate gene 
concept. A drawback of the studies employing such a methodology always lies in fear that 
positive associations may be apparent and negative results a consequence of inadequate 
statistical power.  
In the present study, it was only the MTHFR C677T polymorphism that proved to be 
an independent risk factor for ischemic stroke in multivariate logistic regression; however, as 
genetic sum was superior to particular polymorphisms in predicting ischemic stroke, the 
MTHFR C677T polymorphism was not included in the final model due to nonsignificance of 
other polymorphisms constituting a unified prediction system. Other studies of the MTHFR 
C677T polymorphism association with ischemic stroke have produced contradictory results. 
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Most of the studies found mild yet statistically significant association with ischemic stroke, 
and it seems that the risk increase was mainly mediated by elevated homocysteine levels 
[10,20].  
Multivariate logistic regression confirmed the genetic sum as a continuous variable to 
be a statistically significant and independent risk factor for ischemic stroke (OR 2.315; 
95%CI 1.643-3.260). This result is important for confirming the hypothesis on the synergistic 
gene interplay. Similar analyses have rarely been reported in published studies. Pezzini et al. 
found that odds ratio for ischemic stroke was 1.73 with 95%CI 1.20-2.51 in subjects with one 
prothrombotic polymorphism and 3.00 with 95%CI 1.43-6.30 in those with two or more 
polymorphisms [6]. 
The possibility of systematic error was obviated by double blind study protocol, so 
that the neurologist was blinded for the molecular diagnosis results on the study 
polymorphisms, whereas laboratory personnel were blinded for the rest of diagnostic work-up 
and classification of study subjects. 
A drawback of this and other similar studies is the fact that it was a hospital based pair 
study. As the control group consisted of subjects treated at the same institution for other 
health problems, the possibility of systematic error in pair matching due to population 
complexity cannot be excluded. Yet, as the frequency of study polymorphisms recorded in 
control group corresponded to those in other groups of healthy individuals from a wider area 
of south-east Europe, we believe that the possible systematic error had no impact in our study. 
Like most of the previous studies, our study results do not support genetic testing for 
susceptibility to hypercoagulability in unselected patients, but suggest its possible use and 
benefit in some younger age patients, primarily those where the etiology of ischemic stroke 
remains obscure even after comprehensive and thorough diagnostic work-up [21-24]. Our 
study pointed to the importance and impact of genetic burden, i.e. presence of multiple gene 
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polymorphisms in a particular patient, as an independent risk factor for overall ischemic 
stroke risk development. This opens the possibility of further research and use of novel 
preventive and therapeutic strategies in the management of ischemic stroke. 
Conflict of interest: None. 
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Table 1. Distribution of classic vascular risk factors and studied polymorphisms in 
ischemic stroke patients and control subjects 
 
 
 
F II = prothrombin; F V = coagulation factor V Leiden; MTHFR = 
methylenetetrahydrofolate reductase; PAI-1 = plasminogen activator inhibitor-1; GG 
= genotype guanine guanine; GA = genotype guanine adenine; AA = genotype 
adenine adenine;  CC = genotype cytosine cytosine; CT = genotype cytosine thymine; 
 
Risk 
factor/studied 
polymorphisms 
 
Ischemic 
stroke 
patients 
 
 
Control subjects 
 
p-value 
 
 
OR 
 
 
95%CI  
n % n % 
 
Hypertension 
58 37.4 28 18.7 p<0.001 2.604 1.543-4.405 
 
Obesity 
31 20.0 17 11.3 p=0.001 1.957 1.031-3.704 
 
Diabetes 
12 3.9 9 3.0 p=0.548 1.314 0.537-3.215 
 
Smoking 
70 45.2 36 24.0 p<0.001 2.611 1.597-4.255 
Elevated total 
cholesterol 
97 62.6 79 52.7 p=0.080 1.504 0.952-2.375 
Elevated LDL-
cholesterol 
99 63.9 78 52.0 p=0.036 1.631 1.032-2.577 
Decreased HDL-
cholesterol 
55 35.5 19 12.7 p<0.001 3.792 2.117-6.792 
Elevated 
triglycerides 
57 37.0 51 34.0 p=0.583 1.140 0.713-1.825 
 
F II 
GG 148 95.5 148 98.7  
p=0.174 
 
3.496 
 
0.715-17.241 GA 7 4.5 2 1.3 
AA 0 0 0 0 
 
F V 
GG 141 91.0 145 96.7  
p=0.40 
 
2.882 
 
1.010-8.197 GA 12 7.7 5 3.3 
AA 2 1.3 0 0 
 
MTHFR 
CC 41 26.5 75 50  
p<0.001 
 
2.778 
 
1.721-4.484 CT 78 50.3 59 39.3 
TT 36 23.2 16 10.7 
 
PAI-1 
5G/5G 60 38.7 76 50.7  
p=0.060 
 
1.626 
 
1.032-2.564 4G/5G 51 32.9 46 30.7 
4G/4G 44 28.4 28 18.7 
TT = genotype thymine thymine; 5G = genotype 5 guanine in a sequence; 4G = 
genotype 4 guanine in a sequence 
Table 2. Total number of study factor polymorphisms (genetic sum) in individual 
ischemic stroke patients and control subjects 
 
 
 
 
 
Genetic sum 
 
Ischemic stroke patients 
 
 
Control subjects 
n % n % 
0 15 9.7 40 26.7 
1 64 41.3 65 43.3 
2 62 40.0 44 29.3 
3 14 9.0 1 0.7 
4 0 0 0 0 
 
p<0.001 
Table 3. Total number of study factor polymorphisms (genetic sum) in group of 
patients with non-cryptogenic stroke, cryptogenic stroke and control group. 
 
 
 
 
 
Genetic sum 
 
Patients 
 
 
 
Control subjects  
(n=150) 
 
Non-crpytogenic 
stroke 
(n=99) 
 
 
Cryptogenic stroke 
(n=56) 
n % n % n % 
0 14 14,1 1 1,8 40 26,7 
1 49 49,5 15 26,8 65 43,3 
2 31 31,3 31 55,4 44 29,3 
3 5 5,1 9 16,1 1 0,7 
 
p<0,001 
 
Table 4. Final model of logistic regression of the risk factor significance in ischemic 
stroke development 
 
 
 
Variable 
 
 
p 
 
 
OR 
 
95%CI 
 
Lower 
 
Upper 
Age 0.028 0.967 0.938 0.996 
Decreased HDL-cholesterol 0.000 4.618 2.381 8.957 
Hypertension 0.001 2.839 1.519 5.305 
Obesity 0.040 2.148 1.036 4.457 
Smoking 0.001 2.502 1.436 4.359 
Genetic sum 0.000 2.307 1.638 3.250 
Constant 0.253 0.478   
 
 
OR = odds ratio; 95%CI = 95% confidence interval 
 
